Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib with R-CHOP for CD5-positive DLBCL (Rocket Trial)
NCT06647940Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Started Nov 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06647940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647940.